|
Characteristics
|
Patients, n (%)
|
Median (range)
|
|---|
|
Sex
|
|
Male
|
101 (49.0)
| |
|
Female
|
105 (51.0)
| |
|
Age at diagnosis, year
| |
43 (13–76)
|
|
≥ 43
|
106 (51.5)
| |
|
< 43
|
100 (48.5)
| |
|
BM blasts, %
| |
67.2 (22–97.8)
|
|
≥ 67.2
|
100 (48.5)
| |
|
< 67.2
|
99 (48.1)
| |
|
Unknown
|
7 (3.4)
| |
|
WBC, ×109/L
| |
20.7 (0.29–412.5)
|
|
≥ 20.7
|
104 (50.5)
| |
|
< 20.7
|
102 (49.5)
| |
|
Hemoglobin, g/L
| |
81 (20–138)
|
|
≥ 81
|
103 (50.0)
| |
|
< 81
|
101 (49.0)
| |
|
Unknown
|
2 (1.0)
| |
|
Platelets, ×109/L
|
206
|
38.5 (5–542)
|
|
< 38.5
|
103 (50)
| |
|
≥ 38.5
|
103 (50)
| |
|
FAB classification
|
|
M0
|
2 (1.0)
| |
|
M1
|
14 (6.8)
| |
|
M2
|
104 (50.5)
| |
|
M4
|
31 (15.0)
| |
|
M5
|
46 (22.3)
| |
|
M6
|
7 (3.4)
| |
|
M7
|
2 (1.0)
| |
|
Risk stratificationsa
|
|
Low risk
|
35 (17.0)
| |
|
Intermediate risk
|
118 (57.3)
| |
|
High risk
|
53 (25.7)
| |
|
FLT3-ITD mutation
|
|
Positive/negative
|
25/181 (12.1/87.9)
| |
|
NPM1 mutation
|
|
Positive/negative
|
32/174 (15.5/84.5)
| |
|
KIT mutation
|
|
Positive/negative
|
9/197 (4.4/95.6)
| |
|
CEBPA mutation
|
|
Positive/negative
|
7/199 (3.4/96.6)
| |
|
Karyotype
|
|
Normal
|
133 (64.6)
| |
|
inv (16)
|
8 (3.9)
| |
|
t (8;21)
|
11 (5.3)
| |
|
t (6;9)
|
3 (1.5)
| |
|
t (9;22)
|
1 (0.5)
| |
|
t (9;11)
|
2 (1.0)
| |
|
inv (3)
|
1 (0.5)
| |
|
+ 8
|
2 (1.0)
| |
|
− 7
|
1 (0.5)
| |
|
Other
|
44 (21.4)
| |
|
Treatment response
|
|
CR
|
176 (85.4)
| |
|
CR after 1st course
|
125 (60.7)
| |
|
CR after 2nd course
|
51 (24.8)
| |
|
Non-CR
|
30 (14.6)
| |
|
Treatment outcome
|
|
Death
|
31 (15.0)
| |
|
Relapse
|
21 (10.2)
| |
|
Adverse events (grade ≥ 2)
|
|
Myelosuppression
|
168 (81.6)
| |
|
Liver function damage
|
23 (11.2)
| |
|
Cardiotoxicity
|
11 (5.3)
| |
|
Gastrointestinal reaction
|
66 (32.0)
| |
-
BM bone marrow, WBC white blood cell, FAB French–American–British
-
aClassified according to NCCN guidelines version 1.2015 acute myeloid leukemia
